Xanthine oxidase inhibitor; decreases uric acid production. Prepn: Robins, J. Am. Chem. Soc. 78, 784 (1956); Schmidt, Druey, Helv. Chim. Acta 39, 986 (1956); Druey, Schmidt, US 2868803 (1959 to Ciba); GB 798646 (1958 to Wellcome Found.); Hitchings, Falco, US 3474098 (1969 to Burroughs Wellcome). Physiological and biochemical studies: Hitchings, in Biochem. Aspects Antimetab. Drug Hydroxylation, D. Shugar, Ed. (Academic Press, London, 1969) pp 11-22, C.A. 75, 3531h (1971). Clinical trial in treatment of renal calculi: M. J. V. Smith, J. Urol. 117, 690 (1977); B. Ettinger et al., N. Engl. J. Med. 315, 1386 (1986). Use in hyperuricemia and gout: G. R. Boss, J. E. Seegmiller, ibid. 300, 1459 (1977). Effect on renal function in treatment of gout: T. Gibson, Ann. Rheum. Dis. 41, 59 (1982). Comprehensive description: S. A. Benezra, T. R. Bennett, Anal. Profiles Drug Subs. 7, 1-17 (1978).
Treatment of hyperuricemia and chronic gout. Antiurolithic.
Antigout; Antiurolithic; Xanthine Oxidase Inhibitor